A good example of such dichotomy are the CD19-CAR-T products, whereby Novartis (Kymriah) has recently approved CAR-Ts for Acute Lymphoblastic Leukemia (ALL), and soon to be approved to treat Non-Hodgkin’s lymphoma (NHL), while Gilead CD19-CAR-T cell products (Yescarta) are approved to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and NHL (after two or more than 2 lines of systemic therapy), and soon to approved to treat ALL. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.